Bharat Biotech’s Covaxin 81pc efficient in Phase 3 trials
Vaccine major Bharat Biotech on Wednesday said its COVID-19 vaccine Covaxin has demonstrated an interim vaccine efficacy of 81 percent in Phase 3 clinical trials.The trials involved 25,800 subjects, the…